AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00634790
Drug: alprazolam XR
RxNorm normalized name: ALPRAZOLAM 2 mg ORAL TABLET, EXTENDED RELEASE [Alprazolam XR]
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
Trial: NCT01650272
Drug: 5% MInoxidil milky lotion
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
Trial: NCT01650272
Drug: 5% Minoxidil solution
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL SPRAY [GZE 5% Minoxidil Solution]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receive 5% Minoxidil solution (Propylene glycol solvent )
Trial: NCT03104257
Drug: [11-C]OMAR
DrugBank: Cobomarsen (DB14931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Trial: NCT01164995
Drug: MK-1775 and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
Trial: NCT01608841
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 100 mg 1# PO qd till disease progression
Trial: NCT00787501
Drug: SSRI
RxNorm normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.
Trial: NCT04117698
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethambutol
Trial: NCT02033239
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
Trial: NCT02033239
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
Trial: NCT00237263
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00737633
Drug: VI-0521
RxNorm normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
Trial: NCT01204762
Drug: PegIFN lambda
RxNorm normalized name: Immunoglobulin g1-lambda, anti-(human tissue factor pathway inhibitor (tfpi, extrinsic pathway inhibitor, epi, lipoprotein-associated coagulation inhibitor, laci))
DrugBank: Lamb (DB10537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
Trial: NCT01204762
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
Trial: NCT00439374
Drug: 17 alpha-hydroxyprogesterone caproate
RxNorm normalized name: 17-alpha-hydroxyprogesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
Trial: NCT03574402
Drug: Avitinib Maleate
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg orally (PO) twice daily (BID) on day 1-28.
Trial: NCT03574402
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 40mg orally once a day, 28 days as one cycle.
Trial: NCT03574402
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 250mg PO QD on days 1-28. 28 days as one cycle.
Trial: NCT03574402
Drug: X-396
RxNorm normalized name: X-396
DrugBank: X-396 (DB13104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 225mg PO QD on days 1-28. 28 days as one cycle.
Trial: NCT03574402
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 30mg orally twice weekly, 28 days as one cycle.
Trial: NCT03574402
Drug: Pyrotinib Maleate
RxNorm normalized name: maleate
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg PO QD on days 1-28. 28 days as one cycle.
Trial: NCT03574402
Drug: Pirotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg PO QD/40mg PO BID on days 1-28. 28 days as one cycle.
Trial: NCT03574402
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg, iv gtt. on day 1,8,15. 21 days as one cycle.
Trial: NCT03574402
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500mg/m\^2, iv gtt. Q3W. 21 days as one cycle.
Trial: NCT03574402
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m\^2, iv gtt. Q3W on day1. 21 days as one cycle.
Trial: NCT03574402
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg iv gtt. Q3W on day1. 21 days as one cycle.
Trial: NCT03574402
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
Trial: NCT03574402
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.25g/m\^2 iv gtt. on day1,8. 21 days as one cycle.
Trial: NCT03574402
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AUC5 iv gtt. Q3W on day1. 21 days as one cycle.
Trial: NCT02169856
Drug: Tab. Midazolam 7.5 mg
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
Trial: NCT02169856
Drug: Inj. Midazolam 0.7mg/kg
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
Trial: NCT02169856
Drug: Inj. Propofol 2.5mg/kg
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was given to induce anesthesia after 3 min of pre oxygenation.
Trial: NCT02169856
Drug: Inj. Atracurium 0.5 mg/kg
DrugBank: Atracurium besylate (DB00732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It was given to induce muscle relaxation during anesthesia
Trial: NCT02169856
Drug: Sevoflurane 2.5 vol %
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
Trial: NCT02169856
Drug: Inj. Cefuroxime 1.5 g IV
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
Trial: NCT01147848
Drug: Fluticasone furoate/Vilanterol Inhalation Powder
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
Trial: NCT01147848
Drug: Fluticasone propionate/salmeterol Inhalation Powder
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
Trial: NCT03783182
Drug: Betamethason Sodium Phosphate
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucocorticoid
Trial: NCT00685737
Drug: 1-MNA
RxNorm normalized name: 1-Octacosanol
DrugBank: Octacosanol (DB11220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT04042727
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
Trial: NCT00997360
Drug: PKI-179
RxNorm normalized name: PKI-179
DrugBank: PKI-179 (DB13109)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02281669
Drug: Pentostam
RxNorm normalized name: Pentostam
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of Pentostam
Trial: NCT04534231
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine transdermal patches as per product monograph
Trial: NCT02769286
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
Trial: NCT00353717
Drug: cetuximab paclitaxel
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
Trial: NCT00004827
Drug: docosahexaenoic acid
RxNorm normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04506034
Drug: lidocaine patches
RxNorm normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Patches]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.
Trial: NCT04506034
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.
Trial: NCT04365010
Drug: Sodium Bicarbonate Ringer's Injection
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
Trial: NCT04365010
Drug: 0.9% Sodium Chloride Injection
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For each month of the trial, participating ICUs were assigned to use either Sodium Bicarbonate Ringer's Injection or 0.9% Saline for any intravenous administration of isotonic crystalloid. ICUs were randomly assigned to use Sodium Bicarbonate Ringer's Injection during even-numbered months and 0.9% Saline during odd-numbered months, or vice versa.
Trial: NCT01480323
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
Trial: NCT01480323
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion, 3 mg/kg, day 2, 23, 44, 65
Trial: NCT02267681
Drug: Alfentanil
RxNorm normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alfentanyl for sedation/analgesia
Trial: NCT02267681
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol for sedation
Trial: NCT02790164
Drug: Esmeron
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular Blockade
Trial: NCT02790164
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT00195910
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg IV morphine
Trial: NCT00195910
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.015 mg/kg IV hydromorphone
Trial: NCT03563365
Drug: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved topical agent for the treatment of acne
Trial: NCT03854383
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
Trial: NCT03854383
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used intravaginally to ripe the cevix in induction of labor
Trial: NCT01153698
Drug: dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation
Trial: NCT01554995
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg (Cohort 9) none
Trial: NCT01143584
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point.
Trial: NCT01143584
Drug: cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~1. mg twice a week - second week 1.5 mg twice a week - third week~2. mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also \>50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk.
Trial: NCT02332291
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10-20mg daily
Trial: NCT02332291
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL 150-450mg daily
Trial: NCT03549715
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg IV D1 every 28 days (2 doses for each patient)
Trial: NCT03549715
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg IV D1 every 28 days ((2 doses for each patient)
Trial: NCT00025246
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT00268450
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
Trial: NCT00845663
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
Trial: NCT00268450
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
Trial: NCT00845663
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
Trial: NCT03806270
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Demizolam 15mg/ml ampules, given orally with cherry juice
Trial: NCT03806270
Drug: Hydroxyzine Dihydrochloride
RxNorm normalized name: HYDROXYZINE DIHYDROCHLORIDE
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atarax 2mg/ml syrup, given orally
Trial: NCT03528070
Drug: Tranilast
RxNorm normalized name: Tranilast
DrugBank: Tranilast (DB07615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with tranilast
Trial: NCT00956345
Drug: nonacog beta pegol
RxNorm normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
Trial: NCT00956345
Drug: nonacog beta pegol
RxNorm normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
Trial: NCT00956345
Drug: nonacog beta pegol
RxNorm normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
Trial: NCT00085449
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00085449
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00085449
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00085449
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00268450
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
Trial: NCT01410214
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
Trial: NCT03776955
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01410214
Drug: vinorelbine/cisplatin
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.